semaglutide pdufa Exciting Phase 3 Data from Novo Nordisk for Patients with MASH 💉 The FDA has approved

Mounjaro for weight loss utilizes tirzepatide, which targets both GLP-1 and GIP receptors for potentially enhanced effectiveness

Benefit from the placebo effect of microdoses (the placebo effect is the perceived effect of a drug that leads to an improvement in health)

When the original reporting on GLP-1 gene therapy circulated in late 2025, Fractyl was still primarily discussing rodent data

FDA announced it is hosting a two-day hybrid workshop in partnership with the University of Maryland Center of Excellence in Regulatory Science and Innovation to discuss developing antihypertensive therapies for pediatric patients

Viral supernatants were harvested twice at 48- and 72-hrs post-transfection

The development of novel dual- or triple-receptor agonists that bind to the receptors not only for GLP-1 but also to the receptors for glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon is intended to address different metabolic pathways for carbohydrate, lipid, and protein metabolism simultaneously